107 related articles for article (PubMed ID: 25586095)
21. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
[TBL] [Abstract][Full Text] [Related]
22. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
23. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer.
Drenberg CD; Saunders BO; Wilbanks GD; Chen R; Nicosia RF; Kruk PA; Nicosia SV
Gynecol Oncol; 2010 Apr; 117(1):117-24. PubMed ID: 20071014
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
25. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer.
Odunsi K; Ghamande S; Chandrasekaran EV; Ta A; Moysich KB; Driscoll D; Matta K; Lele S
Am J Obstet Gynecol; 2002 Sep; 187(3):575-80. PubMed ID: 12237630
[TBL] [Abstract][Full Text] [Related]
27. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
[TBL] [Abstract][Full Text] [Related]
28. HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas.
Masciullo V; Baldassarre G; Pentimalli F; Berlingieri MT; Boccia A; Chiappetta G; Palazzo J; Manfioletti G; Giancotti V; Viglietto G; Scambia G; Fusco A
Carcinogenesis; 2003 Jul; 24(7):1191-8. PubMed ID: 12807722
[TBL] [Abstract][Full Text] [Related]
29. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
30. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.
Simon I; Zhuo S; Corral L; Diamandis EP; Sarno MJ; Wolfert RL; Kim NW
Cancer Res; 2006 Feb; 66(3):1570-5. PubMed ID: 16452214
[TBL] [Abstract][Full Text] [Related]
31. Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells.
Treff NR; Dement GA; Adair JE; Britt RL; Nie R; Shima JE; Taylor WE; Reeves R
Oncogene; 2004 Nov; 23(52):8557-62. PubMed ID: 15378028
[TBL] [Abstract][Full Text] [Related]
32. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer.
Robertson DM; Stephenson T; Pruysers E; McCloud P; Tsigos A; Groome N; Mamers P; Burger HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):816-24. PubMed ID: 11836327
[TBL] [Abstract][Full Text] [Related]
33. Nidogen-1: a candidate biomarker for ovarian serous cancer.
Li L; Zhang Y; Li N; Feng L; Yao H; Zhang R; Li B; Li X; Han N; Gao Y; Xiao T; Wu L
Jpn J Clin Oncol; 2015 Feb; 45(2):176-82. PubMed ID: 25378651
[TBL] [Abstract][Full Text] [Related]
34. Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay.
Chien CH; Huang CC; Lin YH; Shen J; Chow SN
Gynecol Oncol; 1997 Sep; 66(3):405-10. PubMed ID: 9299253
[TBL] [Abstract][Full Text] [Related]
35. [Clinical analysis of benign pelvic mass with high serum levels of CA(125)].
Zhang X; Wu LY; Li XJ; Li HJ; Zhang R; Liu LY
Zhonghua Fu Chan Ke Za Zhi; 2005 Mar; 40(3):178-82. PubMed ID: 15840313
[TBL] [Abstract][Full Text] [Related]
36. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor.
Flyvbjerg A; Mogensen O; Mogensen B; Nielsen OS
J Clin Endocrinol Metab; 1997 Jul; 82(7):2308-13. PubMed ID: 9215312
[TBL] [Abstract][Full Text] [Related]
37. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Gynecol Oncol; 2005 Feb; 96(2):516-9. PubMed ID: 15661245
[TBL] [Abstract][Full Text] [Related]
38. Validation of serum biomarkers for detection of early-stage ovarian cancer.
Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
[TBL] [Abstract][Full Text] [Related]
39. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
40. Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer.
Pothacharoen P; Siriaunkgul S; Ong-Chai S; Supabandhu J; Kumja P; Wanaphirak C; Sugahara K; Hardingham T; Kongtawelert P
J Biochem; 2006 Oct; 140(4):517-24. PubMed ID: 16936295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
